Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02468661
Title A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Capmatinib

Capmatinib + Erlotinib

Erlotinib

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL

Facility Status City State Zip Country Details
Los Angeles Hematology/Oncology Medical Group Los Angeles California 90017 United States Details
University of California Irvine Medical Center Chao Family SC Orange California 92868 United States Details
Henry Ford Hospital SC Detroit Michigan 48202-2689 United States Details
Dartmouth Hitchcock Medical Center SC Lebanon New Hampshire 03756 United States Details
Seattle Cancer Care Alliance Seattle Washington 98105 United States Details
Novartis Investigative Site Brussel 1090 Belgium Details
Novartis Investigative Site Charleroi 6000 Belgium Details
Novartis Investigative Site Nice Cedex 2 Alpes Maritimes 06189 France Details
Novartis Investigative Site Bordeaux 33076 France Details
Novartis Investigative Site Caen Cedex 14021 France Details
Novartis Investigative Site Marseille cedex 05 13385 France Details
Novartis Investigative Site Strasbourg Cedex 67091 France Details
Novartis Investigative Site Tübingen Baden-Wuerttemberg 72076 Germany Details
Novartis Investigative Site Regensburg Bavaria 93053 Germany Details
Novartis Investigative Site Berlin 13125 Germany Details
Novartis Investigative Site Bergamo BG 24127 Italy Details
Novartis Investigative Site Brescia BS 25123 Italy Details
Novartis Investigative Site Meldola FC 47014 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Parma PR 43100 Italy Details
Novartis Investigative Site Verona VR 37126 Italy Details
Novartis Investigative Site Fukuoka-city Fukuoka 811-1395 Japan Details
Novartis Investigative Site Akashi Hyogo 673-8558 Japan Details
Novartis Investigative Site Sendai city Miyagi 980 0873 Japan Details
Novartis Investigative Site Okayama-city Okayama 700-8558 Japan Details
Novartis Investigative Site Seoul Korea 05505 Korea, Republic of Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
NKI-AVL, Department of Thoracic-Oncology Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Singapore 169610 Singapore Details
Novartis Investigative Site Sevilla Andalucia 41013 Spain Details
Novartis Investigative Site Barcelona Catalunya 08036 Spain Details
Novartis Investigative Site Madrid 28046 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field